RAPT Q3 2021 Earnings — RAPT Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RAPTRAPT Therapeutics, Inc.

$959M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$966,000-36.8% YoY

Gross Profit

$966,000100.0% margin

Operating Income

-$19M-1918.5% margin

Net Income

-$19M-1930.7% margin

EPS (Diluted)

$-5.06

QoQ Revenue Growth

+11.2%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$217M

Total Liabilities

$16M

Stockholders' Equity

$202M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$966,000	$2M	-36.8%
Gross Profit	$966,000	$2M	-36.8%
Operating Income	-$19M	-$15M	-27.1%
Net Income	-$19M	-$15M	-27.5%